Artelo Biosciences Q2 net loss narrows as R&D expenses fall
Artelo Biosciences Q2 net loss narrows as R&D expenses fall
Overview
Clinical-stage pharmaceutical firm's Q2 net loss narrowed yr/yr
R&D expenses for Q2 decreased, while G&A expenses rose yr/yr
Company completed $11.0 mln financing, strengthening balance sheet
Outlook
Artelo plans to begin a Phase 1 multiple ascending dose study for ART26.12 in Q4 2026
Company expects to start human clinical studies for ART12.11 in the first half of 2026
Company is conducting a fully funded Phase 2 clinical study in glaucoma for ART27.13
Result Drivers
LOWER R&D SPENDING - Co reported a decrease in research and development expenses for Q2 2026 compared to prior yr
Company press release: ID:nGNX3CXfKF
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Loss Per Share |
| $0.89 |
|
Q2 Net Loss |
| $2.40 mln |
|
Analyst Coverage
The one available analyst rating on the shares is "hold"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Reuters Recommended Reads
Aug 11 - Gain Therapeutics Q2 net loss per share narrows as R&D expenses fall
Aug 12 - TScan Therapeutics Q2 net loss narrows on lower R&D costs
Aug 11 - UK's Mereo BioPharma Q2 loss narrows on lower R&D spending
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)